Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Progyny ( (PGNY) ) has provided an update.
Progyny reported record first‑quarter 2026 revenue of $328.5 million on May 7, 2026, with growth in both fertility and pharmacy benefit services despite the loss of a large client that contributed $31.3 million in revenue a year earlier. Excluding that client, revenue rose 12.2% as gross profit increased 10% and gross margin expanded to 25.3%, while net income climbed to $24.2 million, helped by lower stock‑based compensation and higher operating profit.
Adjusted EBITDA edged down 2.1% to $56.6 million as planned investments in platform enhancements outpaced gross profit gains, compressing the Adjusted EBITDA margin to 17.2%. The company generated $45.9 million in operating cash flow, ended March 31, 2026 with $225.1 million in cash and marketable securities and no debt, and completed a $200 million share repurchase program after buying 8.8 million shares, even as early selling‑season activity and client count growth to 595 reflected robust demand for its family building solutions.
The most recent analyst rating on (PGNY) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Progyny stock, see the PGNY Stock Forecast page.
Spark’s Take on PGNY Stock
According to Spark, TipRanks’ AI Analyst, PGNY is a Outperform.
The score is driven primarily by strong financial quality (low leverage and robust free cash flow) and a constructive earnings outlook with record results and ongoing buybacks. These positives are tempered by weak technical momentum (price below key moving averages with negative MACD) and a relatively high P/E with no dividend yield support.
To see Spark’s full report on PGNY stock, click here.
More about Progyny
Progyny, Inc. is a New York‑based provider of women’s health and family building benefits solutions, delivering fertility and pharmacy benefit services to employer clients and their covered members. The Nasdaq‑listed company focuses on cost‑effective fertility care, leveraging a specialized care management platform to improve clinical outcomes and control costs for corporate customers and patients.
Average Trading Volume: 1,497,906
Technical Sentiment Signal: Sell
Current Market Cap: $1.46B
For an in-depth examination of PGNY stock, go to TipRanks’ Overview page.